Lysergic Acid Diethylamide (LSD) in Palliative Care

• Status: Not yet recruiting
• Trial end date: 2027-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects.

Objective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Collaborator: University Hospital, Zürich
• Treatments: Lysergic Acid Diethylamide

Criteria

Inclusion Criteria:

• Age ≥ 25 years.

• End-stage fatal disease of any cause with a life expectancy ≥ 12 weeks and ≤ 2 years

• Sufficient understanding of the study procedures and risks associated with the study.

• Participants must be willing to adhere to the study procedures and sign the consent form.

• Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD administration.

• Participants must complete an actual "Emergency Medical Directive"

Exclusion Criteria:

• Life expectancy < 12 weeks

• Known hypersensitivity to LSD

• Requiring ongoing concomitant therapy with a psychoactive prescription drug which might interfere with the study drug, and unable or unwilling to comply with the washout period.

• Current use of a potent drug CYP2D6 inhibitor

• Women who are pregnant or nursing or intend to become pregnant during the course of the study.

• Somatic disorders including CNS involvement of cancer, epilepsy with a history of seizures, history of delirium, end-stage heart failure (NYHA IV), untreated hypertension or insufficiently treated hypertension, angina pectoris, severe liver disease or severely impaired renal function, or other that in the judgement of the investigators pose too great potential for side effects.

• Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant.

• Participation in another study with an investigational drug within the 30 days preceding and during the present study

• concomitant diagnosis of past or present psychotic disorder

• concomitant diagnosis of past or present bipolar disorder

• substance use disorder (within the last 2 months, except nicotine, opioids used for analgesia, and benzodiazepine treatment for anxiety).

• Weight < 45 kg

• Suicidal ideation with active intent or plan to act on suicidal thoughts as assessed by the treating investigator.